Mass Spectrometry-Based Proteomics: A Useful Tool for Biomarker Discovery?

A biomarker is defined as a biological substance (i.e., protein, metabolite, specific post‐translational modification) that can be used to detect a disease, measure its progression or the effects of a treatment. Importantly, a biomarker should be readily accessible (i.e., present within body fluids)...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2008-05, Vol.83 (5), p.758-760
Main Authors: Gramolini, AO, Peterman, SM, Kislinger, T
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biomarkers - analysis
Biomarkers - blood
Biomarkers - urine
Humans
Mass Spectrometry - methods
Medical sciences
Pharmacology. Drug treatments
Proteomics - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A biomarker is defined as a biological substance (i.e., protein, metabolite, specific post‐translational modification) that can be used to detect a disease, measure its progression or the effects of a treatment. Importantly, a biomarker should be readily accessible (i.e., present within body fluids); it must also provide sufficient sensitivity and specificity to accurately distinguish between true positives, false positives, and false negatives. Even more importantly, detection of the biomarker should provide clinical benefits to the patient (i.e., improved survival and/or quality of life). Due to recent technical advances in biomolecular mass spectrometry, a great deal of effort has gone into the discovery of biomarkers at an international level. In this commentary we set forth our views on how mass spectrometry (MS) could be applied to the discovery of elusive biomarkers (Figure 1). A proteomics‐based biomarker discovery pipeline. A potential biomarker discovery platform could combine global proteomic profiling in tissue (discovery phase) with sensitive quantitation by target‐driven mass spectrometry (MS) (target‐driven validation) of putative biomarkers directly in plasma. ELISA, enzyme‐linked immunosorbent assay; LC‐MS, liquid chromatography–MS; MRM‐MS, multiple reaction monitoring mass spectrometry; MudPIT, multidimensional protein identification technology. Clinical Pharmacology & Therapeutics (2008); 83, 5, 758–760. doi:10.1038/clpt.2008.18
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2008.18